SCHEMBL20552398

SCHEMBL20552398

O=C(O)Cn1nnc(-c2ccccc2Nc2ccc(OC(F)(F)F)cc2)n1

nearest known ligand 0.52

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 7/20 0.52
▸ SMN1; SMN2 Q16637 6/20 0.52
▸ LMNA P02545 5/20 0.49
▸ KMT2A Q03164 7/20 0.49
▸ MEN1 O00255 6/20 0.49
▸ USP2 O75604 2/20 0.48
▸ L3MBTL1 Q9Y468 2/20 0.48
▸ POLB P06746 1/20 0.48
▸ NPC1 O15118 1/20 0.47
▸ RAB9A P51151 1/20 0.47
▸ SCD O00767 1/20 0.45
▸ TP53 P04637 2/20 0.45
▸ HSD17B10 Q99714 2/20 0.45
▸ TSHR P16473 2/20 0.45
▸ KDM4E B2RXH2 2/20 0.45
▸ GAA P10253 1/20 0.44
▸ HPGD P15428 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20553212 0.89 LMNA (0.54) MAPTSMN1; SMN2LMNAKMT2AMEN1
SCHEMBL20552904 0.88 MAPT (0.51) MAPTSMN1; SMN2LMNAKMT2AMEN1
SCHEMBL20552250 0.88 LMNA (0.52) MAPTSMN1; SMN2LMNAKMT2AMEN1
SCHEMBL21749267 0.87 RAB9A (0.57) MAPTSMN1; SMN2LMNAKMT2AMEN1
SCHEMBL20552248 0.87 LMNA (0.51) MAPTSMN1; SMN2LMNAKMT2AMEN1
SCHEMBL20552875 0.86 ABCG2 (0.53) MAPTSMN1; SMN2LMNAKMT2AMEN1
SCHEMBL20553560 0.85 ABL1 (0.45) MAPTSMN1; SMN2LMNAUSP2L3MBTL1
SCHEMBL25786399 0.85 TSHR (0.49) MAPTSMN1; SMN2LMNAKMT2AMEN1
SCHEMBL25786906 0.84 MAPT (0.47) MAPTSMN1; SMN2LMNAKMT2AMEN1
SCHEMBL25786650 0.81 SMN1; SMN2 (0.49) MAPTSMN1; SMN2LMNAKMT2AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11186554-B2 Non-fused tricyclic compounds VIVACE THERAPEUTICS, INC. (US) 2021-11-30 — — US disclosed
US-11186554-B2 Non-fused tricyclic compounds VIVACE THERAPEUTICS, INC. (US) 2021-11-30 — — US disclosed
CN-111132673-A Non-fused tricyclic compounds 维瓦斯治疗公司 2020-05-08 — — CN disclosed
EP-3618818-A1 NON-FUSED TRICYCLIC COMPOUNDS Vivace Therapeutics, Inc. (US) 2020-03-11 — — EP disclosed
US-20200062721-A1 NON-FUSED TRICYCLIC COMPOUNDS VIVACE THERAPEUTICS, INC. 2020-02-27 — — US disclosed
US-20200062721-A1 NON-FUSED TRICYCLIC COMPOUNDS VIVACE THERAPEUTICS, INC. 2020-02-27 — — US disclosed
WO-2018204532-A1 NON-FUSED TRICYCLIC COMPOUNDS VIVACE THERAPEUTICS, INC. (US) 2018-11-08 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200062721-A1 NON-FUSED TRICYCLIC COMPOUNDS YAP1, MYC, TEAD2 MAPT 1705/4885SMN1; SMN2 3160/4885LMNA 2034/4885
US-11186554-B2 Non-fused tricyclic compounds YAP1, MYC, TEAD2 MAPT 1705/4885SMN1; SMN2 3160/4885LMNA 2034/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback